Opioid tolerance and dependence: An inevitable consequence of chronic treatment?

Acta Anaesthesiologica Belgica

Volumn 54, Issue 1, 2003, Pages 37-47

  Adriaensen, Hugo ^a   Vissers, K ^b,c   Noorduin, H ^d   Meert, T ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d NONE

Author keywords

Addiction; Fentanyl; Morphine; Opioids; Physical dependence; Tolerance

Indexed keywords

BUPRENORPHINE; BUTORPHANOL; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; FENTANYL; HYDROMORPHONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; OPIATE; OXYCODONE; PETHIDINE; SUFENTANIL;

ADDICTION; ANALGESIA; ANIMAL MODEL; ANOREXIA; ARTICLE; BINDING AFFINITY; CANCER PAIN; CHRONIC DISEASE; CHRONIC PAIN; CONSTIPATION; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HUMAN; HYPERALGESIA; MORPHINE TOLERANCE; MYOCLONUS; NARCOTIC DEPENDENCE; NAUSEA; NONHUMAN; PAIN; QUALITY OF LIFE; RESPIRATION DEPRESSION; SEDATION; SLOW RELEASE FORMULATION;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG TOLERANCE; HUMANS; OPIOID-RELATED DISORDERS; PAIN;

EID: 0037352199     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Abs R., Verhelst J., Maeyaert J., Van Buyten J. P., Opsomer F., Adriaensen H., Verlooy J., Van Havenbergh T., Smet M., Van Acker K., Endocrine consequences of long-term intrathecal administration of opioids. J. CLIN. ENDOCRINOL. METAB., 85, 2215-2222, 2000.
2. Ahmedzai S., Brooks D., Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group, J. PAIN SYMPTOM MANAGE., 13, 254-261, 1997.
3. Bisaga A., Popik P., In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists, DRUG ALCOHOL DEPEND., 59, 1-15, 2000.
4. Brady L. S., Holtzman S. G., Schedule-controlled behavior in the morphine-dependent and post-dependent rat, PSYCHOPHARMACOLOGY, 70, 11-18, 1980.
5. Brodner R. A., Traub A., Chronic pain exacerbated by longterm narcotic use in patients with non-malignant disease: clinical syndrome and treatment, MT. SINAI J. MED., 45, 233-237, 1978.
6. Brown J. H., Garrett R. L., Relative degree of tolerance to morphine sulfate and methadone hydrochloride in the rat and the interaction of dexamethasone, ARCH. INT. PHARMACODYN. THER., 196, 176-183, 1972.
7. Bruera E., MacMillan K., Hanson J., MacDonald R. N., The cognitive effects of the administration of narcotic analgesics in patients with cancer pain, PAIN, 39, 13-16, 1989.
8. Celerier E., Rivat C., Jun Y., Laulin J. P., Larcher A., Reynier P., Simonnet G., Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine, ANESTHESIOLOGY, 92, 465-472, 2000.
9. Cesselin F., Opioid and anti-opioid peptides, FUNDAM. CLIN. PHARMACOL., 9, 409-433, 1995.
10. Chavkin C., Goldstein A., Opiate receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus, PROC. NATL. ACAD. SCI. USA., 81, 7253-7257, 1984.
11. Chia Y. Y., Liu K., Wang J. J., Kuo M. C., Ho S. T., Intraoperative high dose fentanyl induces postoperative fentanyl tolerance, CAN. J. ANAESTH., 46, 872-877, 1999.
12. Cleeland C. S., The impact of pain on the patient with cancer, CANCER, 54 (Suppl. 11), 2635-2641, 1984.
13. Cleeland C. S., Undertreatment of cancer pain in elderly patients. JAMA, 279, 1914-1915, 1998.
14. Cochin J., Kornetsky C., Development and loss of tolerance to morphine in the rat after single and multiple injections, J. PHARMACOL. EXP. THER., 145, 1-20, 1964.
15. Collin E., Poulain P., Gauvain-Piquard A., Petit G., Pichard-Leandri E., Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment?, PAIN, 55, 319-326, 1993.
16. Colpaert F. C., Can chronic pain be suppressed despite purported tolerance to narcotic analgesia?, LIFE SCI., 24, 1201-1209, 1979.
17. Colpaert F. C., Niemegeers C. J., Janssen P. A., Nociceptive stimulation prevents development of tolerance to narcotic analgesia, EUR. J. PHARMACOL., 49, 335-336, 1978.
18. Cowan A., Lewis J. W., Macfarlane I. R., Agonist and antagonist properties of buprenorphine, a new antinociceptive agent, BR. J. PHARMACOL., 60, 537-545, 1977.
19. Dellemijn P. L. I., van Duijn H., Vanneste J. A. L., Prolonged treatment with transdermal fentanyl in neuropathic pain, J. PAIN SYMPTOM MANAGE., 16, 220-229, 1998.
20. Dole V. P., Narcotic addiction, physical dependence and relapse, N. ENGL. J. MED., 286, 988-992, 1972.
21. Duttaroy A., Yoburn B. C., The effect of intrinsic efficacy on opioid tolerance, ANESTHESIOLOGY, 82, 1126-1136, 1995.
22. Fennessy M. R., Rattray J. F., Cardiovascular effects of intravenous morphine in the anaesthetized rat, EUR. J. PHARMACOL., 14, 1-8, 1971.
23. Fisher K., Coderre T. J., Hagen N. A., Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions, J. PAIN SYMPTOM MANAGE., 20, 358-373, 2000.
24. Foley K., Clinical tolerance to opioids. In: Basbaum A. I., Besson J.-M., eds. Towards a New Pharmacotherapy of Pain. New York: J. Wiley and Sons, 181-203, 1991.
25. Foley K. M., The treatment of cancer pain, N. ENGL. J. MED., 313, 84-95, 1985.
26. France R. D., Urban B. J., Keefe F. J. N., Long-term use of narcotic analgesics in chronic pain, SOC. SCI. MED., 19, 1379-1382, 1984.
27. Gourlay G. K., Cherry D. A., Cousins M. J., A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, PAIN, 25, 297-312, 1986.
28. Herman B. H., Vocci F., Bridge P., The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction, NEUROPSYCHOPHARMACOLOGY, 13, 269-293, 1995.
29. Hill C. S., The barriers to adequate pain management with opioid analgesics, SEMIN. ONCOL., 20 (Suppl. 1), 1-5, 1993.
30. Jaffe J. H., Drug addiction and drug abuse. In: Gilman A. G., Goodman L. S., Rall T. W., Murad F., eds. The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan, 532-581, 1985.
31. Jaffe J. H., Martin W. R., Narcotic analgesics and antagonists. In: Goodman L. S., Gilman A., eds. The pharmacological basis of therapeutics. New York: MacMillan; 245-283, 1975.
32. Jasinski D. R., Human pharmacology of narcotic antagonists, BR. J. CLIN. PHARMACOL., 7 (Suppl. 3), 287S-290S, 1979.
33. Johnson S. M., Duggan A. W., Dependence in the absence of tolerance to morphine, EUR. J. PHARMACOL., 97, 305-308, 1984.
34. Joranson D. E, Ryan K. M, Gilson A. M, Dahl J. L., Trends in medical use and abuse of opioid analgesics, JAMA, 283, 1710-1714, 2000.
35. Joranson D. E., Lietman R., The McNeil National Pain Study. New York: Louis Harris and Associates, 1994.
36. Jurna I., Baldauf J., Zenz M., No psychological dependence after oral administration of morphine to rats, NEUROSCI. LETT., 138, 77-80, 1992.
37. Katz J., Clairoux M., Redahan C., Kavanagh B. P., Carroll S., Nierenberg H., Jackson M., Beattie J., Taddio A., Sandler A. N., High dose alfetanil pre-empts pain after abdominal hysterectomy, PAIN, 68, 109-118, 1996.
38. Kieffer B. L., Evans C. J., Opioid tolerance - in search of the holy grail, CELL, 108, 587-590, 2002.
39. Kissin I., Lee S. S., Arthur G. R., Bradley E. L. Jr., Time course characteristics of acute tolerance development to continuously infused alfentanil in rats, ANESTH. ANALG., 83, 600-605, 1996.
40. Kolb L., Types and characteristics of drug addicts, MENT. HYG., 9, 300, 1925.
41. Lewis J. W., Buprenorphine, DRUG ALCOHOL DEPEND., 14, 363-372, 1985.
42. Louie A. L., Way E. L., Overview of opiate tolerance and physical dependence. In: Almeida O. F., Shippenberg T. S., eds. Neurobiology of Opioids. New York: Springer-Verlag, 1991.
43. Lynch J. J., Stein E. A., Fertziger A. P., An analysis of 70 years of morphine classical conditioning: implications for clinical treatment of narcotic addiction, J. NERV. MENT. DIS., 163, 47-58, 1976.
44. Lyness W. H., Smith F. L., Heavner J. E., Iacono C. U, Garvin R. D., Morphine self-administration in the rat during adjuvant-induced arthritis, LIFE SCI., 45, 2217-2224, 1989.
45. Marshall H., Porteous C., McMillan I., MacPherson S. G., Nimmo W. S., Relief of pain by infusion of morphine after operation: does tolerance develop?, BMJ, (Clin. Res. Ed.), 291, 19-21, 1985.
46. McGivney W. T., Crooks G. M., The care of patients with severe chronic pain in terminal illness, JAMA., 251, 1182-1188, 1984.
47. McQuay H., Pain: opioids in pain management, LANCET, 353, 2229-2232, 1999.
48. Medina J. L., Diamond S., Drug dependency in patients with chronic headache, HEADACHE, 17, 12-14, 1977.
49. Mercadante S., Opioid rotation for cancer pain: rationale and clinical aspects, CANCER, 86, 1856-1866, 1999.
50. Milligan K., Lanteri-Minet M., Borchert K., Helmers H., Donald R., Kress H.-G., Adriaensen H., Moulin D., Järvimäki V., Haazon L., Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain, J. PAIN, 2, 197-204, 2001.
51. Moulin D. E., Iezzi A., Amireh R., Sharpe W. K. J., Boyd D., Merskey H., Randomised trial of oral morphine for chronic non-cancer pain, LANCET, 347, 143-147, 1996.
52. Moulin D. E., Ling G. S. F., Pasternak G. W., Unidirectional analgesic cross-tolerance between morphine and levorphanol in the ratPAIN, 33, 233-239, 1988.
53. Negus S. S., Picker M. J., Dykstra L. A., Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey, J. PHARMACOL. EXP. THER., 256, 149-158, 1991.
54. Onofrio B. M., Yaksh T. L., Long-term pain relief produced by intrathecal morphine infusion in 53 patients, J. NEUROSURG., 72, 200-209, 1990.
55. Page G. G., Ben-Eliyahu S., Yirmiya R., Liebeskind J. C., Morphine attenuates surgery-induced enhancement of metastatic colonization in rats, PAIN, 54, 21-28, 1993.
56. Palm S., Lehzen S., Mignat C., Steinmann J., Leimenstoll G., Maier C., Does prolonged oral treatment with sustained-release morphine tablets influence immune function?, ANESTH. ANALG., 86, 166-172, 1998.
57. Pappagallo M., Heinberg L. J., Ethical issues in the management of chronic nonmalignant pain, SEMIN. NEUROL., 17, 203-211, 1997.
58. Paronis C. A, Holtzman S. G., Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats, J. PHARMACOL. EXP. THER., 262, 1-9, 1992.
59. Payne R., Foley K. M., Advances in the management of cancer pain, CANCER TREAT. REP., 68, 173-183, 1984.
60. Payne R., Mathias S. D., Pasta D. J., Wanke L. A., Williams R., Mahmoud R., Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine, J. CLIN. ONCOL., 16, 1588-1593, 1998.
61. Pchelintsev M. V., Gorbacheva E. N., Zvartau E. E., Simple methodology of assessment of analgesics' addictive potential in mice, PHARMACOL. BIOCHEM. BEHAV., 39, 873-876, 1991.
62. Peloso P. M., Bellamy N., Bensen W., Thomson G. T., Harsanyi Z., Babul N., Darke A. C., Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee, J. RHEUMATOL., 27, 764-771, 2000.
63. Perry S., Heidrich G., Management of pain during debridement: a survey of US burn units, PAIN, 13, 267-280, 1982.
64. Petersen D. W., Fujimoto J. M., Differential tolerance to the intestinal inhibitory effects of opiates in mice, EUR. J. PHARMACOL., 95, 225-230, 1983.
65. Portenoy R. K., Chronic opioid therapy in non-malignant pain, J. PAIN SYMPTOM MANAGE., 5 (Suppl.), S46-S62, 1990.
66. Portenoy R. K., Foley K. M., Chronic use of opioid analgesics in nonmalignant pain: report of 38 cases, PAIN, 25, 171-186, 1986.
67. Portenoy R. K., Opioid therapy for chronic nonmalignant pain : a review of the critical issues, J. PAIN SYMPTOM MANAGE., 11, 203-217, 1996.
68. Portenoy R. K., Savage S. R., Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy - tolerance and addiction, J. PAIN SYMPTOM MANAGE., 14 (Suppl.), S27-S35, 1997.
69. Porter J., Jick H., Addiction rare in patients treated with narcotics, N. ENGL. J. MED., 302: 123, 1980.
70. Rahman A. F., Takahashi M., Kaneto H., Morphine dependence with or without tolerance in formalin-treated mice: further evidence for the dissociation, JPN. J. PHARMACOL., 66, 277-280, 1994.
71. Rayport M., Experience in the management of patients medically addicted to narcotics. JAMA., 156, 684-691, 1954.
72. Riba P., Ben Y., Nguyen T. M., Furst S., Schiller P. W., Lee N. M., [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine, CURR. MED. CHEM., 9, 31-39, 2002.
73. Rogers N. F., el-Fakahany E., Morphine-induced opioid receptor down-regulation detected in intact adult rat brain cells, EUR. J. PHARMACOL., 124, 221-230, 1986.
74. Roth S. H., Fleischmann R. M., Burch F. X., Dietz F., Bockow B., Rapoport R. J., Rutstein J., Lacouture P. G., Aroundthe-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation, ARCH. INTERN. MED., 160, 853-860, 2000.
75. Savage S., Covington E. C., Heit H. A., Hunt J., Joranson D., Schnoll S. H., Definitions Related to the use of opioids for the treatment of pain: A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. http://www.ampainsoc.org/advocacy/opioids2.htm. Accessed April 2002.
76. Savage S. R., Addiction in the treatment of pain: significance, recognition, and management, J. PAIN SYMPTOM MANAGE., 8, 265-278, 1993.
77. Schug S. A., Merry A. F., Acland R. H., Treatment principles for the use of opioids in pain of nonmalignant origin, DRUGS, 42, 228-239, 1991.
78. Schug S. A., Zech D., Grond S., Jung H., Meuser T., Stobbe B., A long-term survey of morphine in cancer pain patients, J. PAIN SYMPTOM MANAGE., 7, 259-266, 1992.
79. Schug S. A., Zech D., Grond S., Morphine doses in the management of cancer pain, PAIN, 5 (Suppl.), S365, 1990.
80. Sees K. L., Clark H. W., Opioid use in the treatment of chronic pain: assessment of addiction, J. PAIN SYMPTOM MANAGE., 8, 257-264, 1993.
81. Smith M. A, Picker M. J., Tolerance and cross-tolerance to the rate-suppressing effects of opioids in butorphanol-treated rats: influence of maintenance dose and relative efficacy at the mu receptor, PSYCHOPHARMACOLOGY, 140, 57-68, 1998.
82. Sosnowski M., Yaksh T. L., Differential cross-tolerance between intrathecal morphine and sufentanil in the rat, ANESTHESIOLOGY, 73, 1141-1147, 1990.
83. Stevens G. W., Yaksh T. L., Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion, J. PHARMACOL. EXP. THER., 250, 1-8, 1989a.
84. Stevens G. W., Yaksh T. L., Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord, J. PHARMACOL. EXP. THER., 251, 216-223, 1989b.
85. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department trends from the Drug Abuse Warning Network, preliminary estimates January-June 2001 with revised estimates 1994 to 2000. DAWN Series D-20, DHHS Publication No. (SMA) 02-3634, Rockville, MD, 2002.
86. Swift J. Q., Roszkowski M. T., The use of opioid drugs in management of chronic orofacial pain, J. ORAL MAXILLOFAC. SURG., 56, 1081-1085, 1998.
87. Taub A., Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kitahata L. M., Collins D., eds. Narcotic Analgesics in Anesthesiology. Baltimore: Williams and Wilkins, 199-208, 1982.
88. Thomsen A. B., Becker N., Eriksen J., Opioid rotation in chronic non-malignant pain patients. A retrospective study, ACTA. ANAESTHESIOL. SCAND., 43, 918-923, 1999.
89. Twycross R. G., Ethical and clinical aspects of pain treatment in cancer patients, ACTA. ANAESTHESIOL. SCAND., 26 (Suppl. 74), 83-90, 1982.
90. Vinik H. R., Kissin I., Rapid development of tolerance to analgesia during remifentanil infusion in humans, ANESTH. ANALG., 86, 1307-1311, 1998.
91. Walsh S. L., Preston K. L., Stitzer M. L., Cone E. J., Bigelow G. E., Clinical pharmacology of buprenorphine: ceiling effects at high doses, CLIN. PHARMACOL. THER., 55, 569-580, 1994.
92. Wang C., Chakrabarti M. K, Whitwam J. G., Lack of a ceiling effect for intrathecal buprenorphine on C fibre mediated somatosympathetic reflexes, BR. J. ANAESTH., 71, 528-533, 1993.
93. Weissman D. E, Haddox J. D., Opioid pseudoaddiction - an iatrogenic syndrome, PAIN, 36, 363-366, 1989.
94. Winkelmuller M., Winkelmuller W., Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology, J. NEUROSURG., 85, 458-467, 1996.
95. World Health Organization, Cancer pain relief and palliative care: Report of a WHO expert committee. World Health Organization Technical Report Series. 2nd edn. WHO, Geneva, Switzerland: 1996.
96. World Health Organization., Technical report no. 516, youth and drugs. WHO, Geneva: 1973.
97. Zenz M., Zenz T., Tryba M., Strumpf M., Severe undertreatment of cancer pain: a 3-year survey of the German situation, J. PAIN SYMPTOM MANAGE,. 10, 187-191, 1995.